Featured Press Releases

AusperBio

AusperBio's AHB-137 Receives Breakthrough Therapy Designation for Chronic Hepatitis B Treatment

FDA Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Relapsed or Refractory Follicular Lymphoma

FDA Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Relapsed or Refractory Follicular Lymphoma

  • 27 Jun 2024

AbbVie announced that the U.S. Food and Drug Administration (FDA) has approved EPKINLY®...

GoodRx has announced a collaboration with Novo Nordisk to offer expanded access to Ozempic® and Wegovy® for $499 per month

GoodRx has announced a collaboration with Novo Nordisk to offer expanded access to Ozempic® and Wegovy® for $499 per month

Mediar Therapeutics partners with Lilly to develop a first-in-class WISP1 antibody for idiopathic pulmonary fibrosis

Mediar Therapeutics partners with Lilly to develop a first-in-class WISP1 antibody for idiopathic pulmonary fibrosis

Fosun Pharma deeply embraces AI, with its self-developed PharmAID Decision Intelligence Platform boosting efficient innovation

Fosun Pharma deeply embraces AI, with its self-developed PharmAID Decision Intelligence Platform boosting efficient innovation

A Korea University study identifies mitochondrial dysfunction as a key factor in cognitive and metabolic impairments, offering insights into potential treatments

A Korea University study identifies mitochondrial dysfunction as a key factor in cognitive and metabolic impairments, offering insights into potential treatments

ImmunoScape Appoints Peter Olagunju as Chief Executive Officer

ImmunoScape Appoints Peter Olagunju as Chief Executive Officer

  • ImmunoScape Pte. Ltd.
  • 23 Sep 2026
LEVEL Relief Protab Reduced Everyday Aches and Pain in an Independent 29-Day Study

LEVEL Relief Protab Reduced Everyday Aches and Pain in an Independent 29-Day Study

  • LEVEL
  • 22 Sep 2026
FDA Updates WINREVAIR™ Label with HYPERION Phase 3 Trial Data in Adults Newly Diagnosed with PAH

FDA Updates WINREVAIR™ Label with HYPERION Phase 3 Trial Data in Adults Newly Diagnosed with PAH

  • Merck & Co., Inc.
  • 22 Sep 2026
Padagis Expands Workplace Naloxone Access by Providing Free Nasal Sprays to Qualifying Businesses

Padagis Expands Workplace Naloxone Access by Providing Free Nasal Sprays to Qualifying Businesses

  • Padagis
  • 21 Sep 2026
StimCardio’s NeuroPulse Study Reports a Substantial Reduction in Recurrent Atrial Fibrillation Events Following Ablation Using Non-Invasive Wearable Neuromodulation

StimCardio’s NeuroPulse Study Reports a Substantial Reduction in Recurrent Atrial Fibrillation Events Following Ablation Using Non-Invasive Wearable Neuromodulation

  • StimCardio’s
  • 21 Sep 2026
Bruker Receives Order for High-Field NMR Systems to Support a Major Upgrade of Magnetic Resonance Research Infrastructure at UC Berkeley.

Bruker Receives Order for High-Field NMR Systems to Support a Major Upgrade of Magnetic Resonance Research Infrastructure at UC Berkeley.

  • Bruker Corporation
  • 21 Sep 2026

Most Popular
September   2026
M T W T F S S
  1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30        

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.